Takeda gains novel drug discovery tech through Envoy acquisition
This article was originally published in Scrip
Takeda's late 2010 research alliance with Envoy Therapeutics has led to the Japanese firm acquiring 100% of the privately held US CNS drug discovery specialist for up to $140 million in cash, in a deal expected to be finalized within the next few days.
You may also be interested in...
The Japanese pharma's new San Diego site brings together scientists from multiple locations to identify and validate therapeutic candidates across multiple modalities to enhance Takeda's global internal and external programs.
In this week's podcast version of Five Must-Know Things: Pfizer to boost migraine presence via M&A; Roche’s immunotherapy ambitions take a hit; Biogen’s CEO search gets more complicated; Stoffels lays out new strategy for Galapagos; and mixed results for Japanese majors.
As Takeda reported what its CEO described as "a remarkable year," the company sees itself as well positioned to ride out the expiries over the next few years of exclusivity for several big-selling products, as it looks to mainstays and more organic growth to tide it over the "temporary headwinds."